{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:49:20Z","timestamp":1791485360785,"version":"4.3.4"},"reference-count":11,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JPGN rep."],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Payer mandates have resulted in children with inflammatory bowel disease (IBD) switching from originator Remicade\u00ae (O\u2010Rem) to an infliximab biosimilar (B\u2010IFX). Patients and families are fearful of switching because disease has been well controlled on O\u2010Rem. Real\u2010world data documenting clinical outcomes after such switches in pediatric patients are limited. The aim of this project was to examine 1 year of follow\u2010up in a large adolescent\/young adult IBD cohort who changed from O\u2010Rem to B\u2010IFX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified patients with IBD at Connecticut Children's receiving O\u2010Rem for at least 1 year, who were either in clinical remission or had low disease activity, and who were subsequently switched to B\u2010IFX. An age, gender, IBD\u2010subtype, and duration since diagnosis cohort that continued on O\u2010Rem was then matched to the switch cohort and served as a comparator group (1: switch vs. 2: no\u2010switch). B\u2010IFX was Inflectra\u00ae in all cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two hundred and seventy\u2010nine patients (mean age 18.7\u2009years, Crohn's disease\u2009=\u2009243, ulcerative colitis\u2009=\u200936) were studied (switch, <jats:italic>n<\/jats:italic>\u2009=\u200993, no\u2010switch, <jats:italic>n<\/jats:italic>\u2009=\u2009186). Mean time since diagnosis was &gt;6 years in both groups, and mean duration of anti\u2010tumor necrosis factor use was &gt;5 years. There were no significant changes in hemoglobin, albumin, C\u2010reactive protein, erythrocyte sedimentation rate, or disease activity in either group over 1 year. Dosing modifications as well as the frequency of low\u2010level antibodies to infliximab were similar in both groups over the study period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Switching from O\u2010Rem to B\u2010IFX has no impact on clinical or laboratory parameters over the subsequent year. Clinicians can reliably reassure patients and families that switching is safe.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jpr3.12134","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:20:01Z","timestamp":1727446801000},"page":"442-446","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Change from originator infliximab to biosimilar does not affect 1\u2010year outcome in children with inflammatory bowel disease"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3544-7182","authenticated-orcid":false,"given":"Viven","family":"Solomon","sequence":"first","affiliation":[{"name":"Division of Digestive Diseases, Hepatology, and Nutrition Connecticut Children's Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Kuzoian","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Hepatology, and Nutrition Connecticut Children's Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genesis","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Connecticut Children's University of Connecticut School of Medicine Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brimacombe","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Pediatrics Connecticut Children's Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-236X","authenticated-orcid":false,"given":"Jeffrey S.","family":"Hyams","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Hepatology, and Nutrition Connecticut Children's Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i5.632"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4661-4"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312388.263"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666161014153346"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv233"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000256"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003750"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003683"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003890"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12153"}],"container-title":["JPGN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpr3.12134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:29:03Z","timestamp":1732710543000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpr3.12134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/jpr3.12134"],"URL":"https:\/\/doi.org\/10.1002\/jpr3.12134","archive":["Portico"],"relation":{},"ISSN":["2691-171X","2691-171X"],"issn-type":[{"value":"2691-171X","type":"print"},{"value":"2691-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"2024-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}